Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CYP3A substrates using a physiologically-based pharmacokinetic model

European Journal of Pharmaceutical Sciences

Volumn 67, Issue , 2015, Pages 32-44

  Olivares Morales, Andrés ^a   Kamiyama, Yoshiteru ^a,b   Darwich, Adam S ^a   Aarons, Leon ^a   Rostami Hodjegan, Amin ^a,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ASTELLAS PHARMA INC   (Japan)

^c CERTARA UK LIMITED   (United Kingdom)

Author keywords

Controlled release formulations; CYP3A; Gut wall metabolism; Oral bioavailability; P glycoprotein; PBPK models

Indexed keywords

CYTOCHROME P450 3A; DELAYED RELEASE FORMULATION;

AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CLINICAL ASSESSMENT; CLINICAL STUDY; COMPARATIVE STUDY; COMPUTER MODEL; CONTROLLED RELEASE FORMULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG SOLUBILITY; FIRST PASS EFFECT; GUT WALL METABOLISM; HUMAN; INTESTINE ABSORPTION; MEMBRANE PERMEABILITY; PHYSICAL CHEMISTRY; SIMULATION; BIOAVAILABILITY; BIOLOGICAL MODEL; DELAYED RELEASE FORMULATION; GASTROINTESTINAL ABSORPTION; METABOLISM; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 CYP3A; DELAYED-ACTION PREPARATIONS; GASTROINTESTINAL ABSORPTION; HUMANS; MODELS, BIOLOGICAL;

EID: 84911448519     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2014.10.018     Document Type: Article

References (71)

1. Alvarez-Lueje, A., Valenzuela, C., Squella, J.A., Nunez-Vergara, L.J., 2005. Stability study of simvastatin under hydrolytic conditions assessed by liquid chromatography. J. AOAC Int. 88, 1631-1636.
2. Amidon, G.L., Lennernas, H., Shah, V.P., Crison, J.R., 1995. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12, 413-420.
3. Benet, L.Z., Broccatelli, F., Oprea, T.I., 2011. BDDCS applied to over 900 drugs. AAPS J. 13, 519-547.
4. Berezhkovskiy, L.M., 2011. The corrected traditional equations for calculation of hepatic clearance that account for the difference in drug ionization in extracellular and intracellular tissue water and the corresponding corrected PBPK equation. J. Pharm. Sci. 100, 1167-1183.
5. Berggren, S., Gall, C., Wollnitz, N., Ekelund, M., Karlbom, U., Hoogstraate, J., Schrenk, D., Lennernäs, H., 2007. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol. Pharm. 4, 252-257.
6. Brown, J., Crison, J., Timmins, P., 2012. Predicting feasibility and characterizing performance of extended-release formulations using physiologically based pharmacokinetic modeling. Ther. Delivery 3, 1047-1059.
7. Bu, H.Z., 2006. A literature review of enzyme kinetic parameters for CYP3A4-mediated metabolic reactions of 113 drugs in human liver microsomes: structure-kinetics relationship assessment. Curr. Drug Metab. 7, 231-249.
8. Comer, A.M., Goa, K.L., 2000. Extended-release oxybutynin. Drugs Aging 16, 149-155, Discussion 156-147.
9. Coupe, A.J., Davis, S.S., Evans, D.F., Wilding, I.R., 1992. Nocturnal scintigraphic imaging to investigate the gastrointestinal transit of dosage forms. J. Controlled Release 20, 155-162.
10. Darwich, A.S., Neuhoff, S., Jamei, M., Rostami-Hodjegan, A., 2010. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "advanced dissolution, absorption, metabolism (ADAM)" model. Curr. Drug Metab. 11, 716-729.
11. Davis, S.S., Hardy, J.G., Fara, J.W., 1986. Transit of pharmaceutical dosage forms through the small intestine. Gut 27, 886-892.
12. Douchamps, J., Derenne, F., Stockis, A., Gangji, D., Juvent, M., Herchuelz, A., 1988. The pharmacokinetics of oxybutynin in man. Eur. J. Clin. Pharmacol. 35, 515-520.
13. European Medicines Agency, 2013. Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms 〈http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2013/03/WC500140482.pdf〉.
14. Fallingborg, J., Christensen, L.A., Ingeman-Nielsen, M., Jacobsen, B.A., Abildgaard, K., Rasmussen, H.H., 1989. PH-profile and regional transit times of the normal gut measured by a radiotelemetry device. Aliment. Pharmacol. Ther. 3, 605-614.
15. Fieller, E.C., 1954. Some problems in interval estimation. J. R. Stat. Soc. Ser, B 16, 175-185.
16. Gammans, R.E., Mayol, R.F., Labudde, J.A., 1986. Metabolism and disposition of buspirone. Am. J. Med. 80, 41-51.
17. Gammans, R.E., Mayol, R.F., MacKenthun, A.V., Sokya, L.F., 1985. The relationship between buspirone bioavailability and dose in healthy subjects. Biopharm. Drug Dispos. 6, 139-145.
18. Gertz, M., Harrison, A., Houston, J.B., Galetin, A., 2010. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab. Dispos. 38, 1147-1158.
19. Gertz, M., Houston, J.B., Galetin, A., 2011. Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. Drug Metab. Dispos. 39, 1633-1642.
20. Gupta, S.K., Sathyan, G., 1999. Pharmacokinetics of an oral once-a-day controlledrelease oxybutynin formulation compared with immediate-release oxybutynin. J. Clin. Pharmacol. 39, 289-296.
21. Gupta, S.K., Sathyan, G., Lindemulder, E.A., Ho, P.-L., Sheiner, L.B., Aarons, L., 1999. Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships. Clin. Pharmacol. Ther. 65, 672-684.
22. Hallifax, D., Foster, J.A., Houston, J.B., 2010. Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view. Pharm. Res. 27, 2150-2161.
23. Hallifax, D., Houston, J.B., 2012. Evaluation of hepatic clearance prediction using in vitro data: emphasis on fraction unbound in plasma and drug ionisation using a database of 107 drugs. J. Pharm. Sci. 101, 2645-2652.
24. Heikkinen, A.T., Baneyx, G., Caruso, A., Parrott, N., 2012. Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates - an evaluation and case study using GastroPlus. Eur. J. Pharm. Sci. 47, 375-386.
25. Jamei, M., Dickinson, G.L., Rostami-Hodjegan, A., 2009a. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab. Pharmacokinet. 24, 53-75.
26. Jamei, M., Marciniak, S., Feng, K., Barnett, A., Tucker, G., Rostami-Hodjegan, A., 2009b. The Simcyp® population-based ADME simulator. Expert Opin. Drug Metab. Toxicol. 5, 211-223.
27. Jamei, M., Turner, D., Yang, J., Neuhoff, S., Polak, S., Rostami-Hodjegan, A., Tucker, G., 2009c. Population-based mechanistic prediction of oral drug absorption. AAPS J. 11, 225-237.
28. Jang, S.B., Lee, Y.J., Lim, L.A., Park, K.M., Kwon, B.J., Woo, J.S., Kim, Y.I., Park, M.S., Kim, K.H., Park, K., 2010. Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. Clin. Ther. 32, 206-216.
29. Langer, R., 1990. New methods of drug delivery. Science 249, 1527-1533.
30. Lennernas, H., 2007. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica 37, 1015-1051.
31. Lennernas, H., 2014a. Human in vivo regional intestinal permeability: importance for pharmaceutical drug development. Mol. Pharm. 11, 12-23.
32. Lennernas, H., 2014b. Regional intestinal drug permeation: biopharmaceutics and drug development. Eur. J. Pharm. Sci. 57, 333-341.
33. Lennernäs, H., Ahrenstedt, Ö., Hällgren, R., Knutson, L., Ryde, M., Paalzow, L., 1992. Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharm. Res. 9, 1243-1251.
34. Lin, J.H., Chiba, M., Baillie, T.A., 1999. Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol. Rev. 51, 135-158.
35. Lukkari, E., Taavitsainen, P., Juhakoskr, A., Pelkonen, O., 1998. Cytochrome P450 specificity of metabolism and interactions of oxybutynin in human liver microsomes. Pharmacol. Toxicol. 82, 161-166.
36. Martinez, M., Amidon, G., 2002. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J. Clin. Pharmacol. 42, 620-643.
37. Mizushima, H., Takanaka, K., Abe, K., Fukazawa, I., Ishizuka, H., 2007. Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo. Xenobiotica 37, 59-73.
38. Motulsky, H., 2010. Intuitive Biostatistics: A Nonmathematical Guide to Statistical Thinking. Oxford University Press.
39. Mouly, S., Paine, M., 2003. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm. Res. 20, 1595-1599.
40. Paine, M.F., Khalighi, M., Fisher, J.M., Shen, D.D., Kunze, K.L., Marsh, C.L., Perkins, J.D., Thummel, K.E., 1997. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther. 283, 1552-1562.
41. Poulin, P., 2013. Prediction of total hepatic clearance by combining metabolism, transport, and permeability data in the in vitro-in vivo extrapolation methods: emphasis on an apparent fraction unbound in liver for drugs. J. Pharm. Sci. 102, 2085-2095.
42. Poulin, P., Kenny, J.R., Hop, C.E.C.A., Haddad, S., 2012. In vitro-in vivo extrapolation of clearance: modeling hepatic metabolic clearance of highly bound drugs and comparative assessment with existing calculation methods. J. Pharm. Sci. 101, 838-851.
43. Prueksaritanont, T., Qiu, Y., Mu, L., Michel, K., Brunner, J., Richards, K., Lin, J., 2005. Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. Pharm. Res. 22, 1101-1109.
44. Roberts, M., Rowland, M., 1986. A dispersion model of hepatic elimination: 1. formulation of the model and bolus considerations. J. Pharmacokinet. Biopharm. 14, 227-260.
45. Rowland, M., Benet, L., Graham, G., 1973. Clearance concepts in pharmacokinetics. J. Pharmacokinet. Biopharm. 1, 123-136.
46. Rowland Yeo, K., Jamei, M., Yang, J., Tucker, G.T., Rostami-Hodjegan, A., 2010. Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. Eur. J. Pharm. Sci. 39, 298-309.
47. Rubinstein, A., 2005. Colonic drug delivery. Drug Discovery Today: Technol. 2, 33-37.
48. Sakr, A., Andheria, M., 2001a. A comparative multidose pharmacokinetic study of buspirone extended-release tablets with a reference immediate-release product. J. Clin. Pharmacol. 41, 886-894.
49. Sakr, A., Andheria, M., 2001b. Pharmacokinetics of buspirone extended-release tablets: a single-dose study. J. Clin. Pharmacol. 41, 783-789.
50. Sathyan, G., Chancellor, M.B., Gupta, S.K., 2001. Effect of OROS® controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. Br. J. Clin. Pharmacol. 52, 409-417.
51. Satoh, T., Taylor, P., Bosron, W.F., Sanghani, S.P., Hosokawa, M., Du, B.N.L., 2002. Current progress on esterases: from molecular structure to function. Drug Metab. Dispos. 30, 488-493.
52. Schiller, C., Frohlich, C.P., Giessmann, T., Siegmund, W., Monnikes, H., Hosten, N., Weitschies, W., 2005. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment. Pharmacol. Ther. 22, 971-979.
53. Shibata, Y., Takahashi, H., Chiba, M., Ishii, Y., 2002. Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method. Drug Metab. Dispos. 30, 892-896.
54. Sinha, V.K., Snoeys, J., Osselaer, N.V., Peer, A.V., Mackie, C., Heald, D., 2012. From preclinical to human - prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example. Biopharm. Drug Dispos. 33, 111-121.
55. Sinko, P.J., Leesman, G.D., Amidon, G.L., 1991. Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharm. Res. 8, 979-988.
56. Sjogren, E., Abrahamsson, B., Augustijns, P., Becker, D., Bolger, M.B., Brewster, M., Brouwers, J., Flanagan, T., Harwood, M., Heinen, C., Holm, R., Juretschke, H.P., Kubbinga, M., Lindahl, A., Lukacova, V., Munster, U., Neuhoff, S., Nguyen, M.A., Peer, A., Reppas, C., Hodjegan, A.R., Tannergren, C., Weitschies, W., Wilson, C., Zane, P., Lennernas, H., Langguth, P., 2014. In vivo methods for drug absorption - comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects. Eur. J. Pharm. Sci. 57, 99-151.
57. Sun, D., Lennernas, H., Welage, L., Barnett, J., Landowski, C., Foster, D., Fleisher, D., Lee, K.-D., Amidon, G., 2002. Comparison of human duodenum and caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm. Res. 19, 1400-1416.
58. Sutton, S., 2009. Role of physiological intestinal water in oral absorption. AAPS J. 11, 277-285.
59. Tannergren, C., Bergendal, A., Lennernas, H., Abrahamsson, B., 2009. Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment. Mol. Pharm. 6, 60-73.
60. Thombre, A.G., 2005. Assessment of the feasibility of oral controlled release in an exploratory development setting. Drug Discovery Today 10, 1159-1166.
61. Troutman, M., Thakker, D., 2003. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across caco-2 cell monolayers. Pharm. Res. 20, 1200-1209.
62. Tubic-Grozdanis, M., Hilfinger, J.M., Amidon, G.L., Kim, J.S., Kijek, P., Staubach, P., Langguth, P., 2008. Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms. Pharm. Res. 25, 1591-1600.
63. U.S. Food and Drug Administration, 2000. Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. 〈http://www.fda.gov/downloads/Drugs/.../Guidances/ucm070246.pdf〉.
64. Watts, P.J., Lllum, L., 1997. Colonic drug delivery. Drug Dev. Ind. Pharm. 23, 893-913.
65. Wilding, I.R., 1999. Evolution of the biopharmaceutics classification system (BCS) to oral modified release (MR) formulations; what do we need to consider? Eur. J. Pharm. Sci. 8, 157-159.
66. Yaich, M., Popon, M., Medard, Y., Aigrain, E.J., 1998. In-vitro cytochrome P450 dependent metabolism of oxybutynin to N-deethyloxybutynin in humans. Pharmacogenetics 8, 449-451.
67. Yang, J., Jamei, M., Yeo, K.R., Tucker, G.T., Rostami-Hodjegan, A., 2007. Prediction of intestinal first-pass drug metabolism. Curr. Drug Metab. 8, 676-684.
68. Yu, L.X., Crison, J.R., Amidon, G.L., 1996. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int. J. Pharm. 140, 111-118.
69. Zhang, Q.-Y., Dunbar, D., Ostrowska, A., Zeisloft, S., Yang, J., Kaminsky, L.S., 1999. Characterization of human small intestinal cytochromes P-450. Drug Metab. Dispos. 27, 804-809.
70. Zhang, X., Lionberger, R.A., 2014. Modeling and simulation of biopharmaceutical performance. Clin. Pharmacol. Ther. 95, 480-482.
71. Zhu, M., Zhao, W., Jimenez, H., Zhang, D., Yeola, S., Dai, R., Vachharajani, N., Mitroka, J., 2005. Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab. Dispos. 33, 500-507.